Plain-English translation of NCT07163910 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, works better when combined with hormone therapy (androgen deprivation therapy) to treat prostate cancer before surgery. You would receive the medication as an intravenous infusion—through an IV—over two consecutive days. The goal is to see if this combination approach helps shrink tumors and improve outcomes before your prostate is surgically removed.
Advanced prostate cancer can spread beyond the prostate gland, making it harder to treat. Doctors want to know if giving this medication before surgery—combined with existing hormone therapy—can help control the cancer more effectively and give patients better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive intravenous infusions of the medication mixed with a glucose solution over two days. Depending on your cancer stage, you may receive one or more cycles of treatment, with breaks between cycles if needed. Throughout this time, you would also take hormone therapy medications continuously. Within three weeks after finishing the medication treatment, you would undergo surgery to remove your prostate. You would then be followed by your medical team to monitor your recovery and health.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China